2956 Levorphanol Levorphanol is an exogenous organic compound with the formula C17H23NO and an average molecular weight of 257.37 g/mol. It exists as a solid at room temperature. Levorphanol belongs to the morphinans, a class of alkaloids and derivatives within the organic compounds. The compound is associated with 21 recorded sources. These include electrical and electronic equipment such as amplifiers, antennas, communication cables or conductors, contacts, and cores yokes or armatures. It is also found in building and construction materials, specifically ceilings and tents or canopies. In the category of food, food processing and cookware, it is linked to the treatment of hops and the preparation of vinegar and wort. Additionally, it is found in household cleaning and consumer products, including pipe accessories, other smoking requisites, and non electric simulated smoking devices. Levorphanol acts on three recorded protein targets: the delta-type opioid receptor (OPRD1), the kappa-type opioid receptor (OPRK1), and the mu-type opioid receptor (OPRM1). Like other mu-agonist opioids, it is believed to act at receptors in the periventricular and periaqueductal gray matter in both the brain and spinal cord to alter the transmission and perception of pain. 77-07-6 5359272 C17H23NO 257.177960 White powder. 198-199°C 1840 mg/L Subcutaneous, Intravenous, or Intramuscular injection ; Oral. Levorphanol is well absorbed after PO administration with peak plasma concentrations occurring approximately 1 hour after dosing. Like other mu-agonist opioids it is believed to act at receptors in the periventricular and periaqueductal gray matter in both the brain and spinal cord to alter the transmission and perception of pain. Levorphanol is extensively metabolized in the liver and is eliminated as the glucuronide metabolite. Half Life: 11-16 hours LD50: 150 mg/kg (Oral, Rat) (A308) No indication of carcinogenicity to humans (not listed by IARC). For the management of moderate to severe pain or as a preoperative medication where an opioid analgesic is appropriate Medical problems can include congested lungs, liver disease, tetanus, infection of the heart valves, skin abscesses, anemia and pneumonia. Death can occur from overdose. Signs of overdose include nausea, emesis, dizziness, respiratory depression, hypotension, urinary retention, cardiac arrhythmias, allergic reactions, skin rash, and uticaria. The specific treatment of suspected levorphanol tartrate overdosage is immediate establishment of an adequate airway and ventilation, followed (if necessary) by intravenous naloxone. The respiratory and cardiac status of the patient should be continuously monitored and appropriate supportive measures instituted, such as oxygen, intravenous fluids and/or vasopressors, if required. Physicians are reminded that the duration of levorphanol action far exceeds the duration of action of naloxone, and repeated dosing with naloxone may be required. Naloxone should be administered cautiously to persons known or suspected to be physically dependent on Levorphanol. In such cases an abrupt and complete reversal of opioid effects may precipitate an acute abstinence syndrome. If necessary to administer naloxone to the physically dependent patient, the antagonist should be administered with extreme care and by titration with smaller than usual doses of the antagonist. (L1712) 2009-07-21T20:27:50Z 2026-05-14T16:50:48Z Levorphanol C08014 119572 Levorphanol DB00854 true [H][C@@]12CCCC[C@@]11CCN(C)[C@@H]2CC2=C1C=C(O)C=C2 C17H23NO InChI=1S/C17H23NO/c1-18-9-8-17-7-3-2-4-14(17)16(18)10-12-5-6-13(19)11-15(12)17/h5-6,11,14,16,19H,2-4,7-10H2,1H3/t14-,16+,17+/m0/s1 JAQUASYNZVUNQP-USXIJHARSA-N 257.3706 257.177964363 Exogenous Solid 3.11 HMDB14992 CHEMBL592 16736212 <p>Joseph P. Haar, &#8220;Process for the Production of Levorphanol and Related Compounds.&#8221; U.S. Patent US20080146805, issued June 19, 2008.</p> CHEM002290 DTXSID3023213 NS00067936 (1R,9R,10R)-17-methyl-17-azatetracyclo[7.5.3.0^{1,10}.0^{2,7}]heptadeca-2(7),3,5-trien-4-ol 23.47 78.08090000000001 29.835843009547546 0 2 1 10.461597359118004 9.65585507934564 1 4 3.29 -3.17 1.73e-01 g/l Organic compounds Alkaloids and derivatives Morphinans 857 CED0008142 JAQUASYNZVUNQP-USXIJHARSA-N 1000000000000100000000000000000000000000000000000004000000040000000000000000020000000100000000002000080000000000000000000100000000000000000000c0000000000000010000000000000000120020000000020108000000000000000000100800000068000000000000080000004000200000000000000000080000000000000000084004000000000000080000000000000000000000008000000000000000000000000000002000000002000000000000400000000010000202000000000000000000000000000040000000000000000000000000080000000000000000 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 776t3gAAAAAQAAAAAwAAAAAAAAATAAAAFgAAAIABBiA0AAAAAgEEBgBgAAAA AgIGAGAAAAACAgYAYAAAAAICBgBgAAAAAgIGICQAAAABBAYAYAAAAAICBgBg AAAAAgIHACAAAAADBgBgAAAAAQMGIDQAAAACAQQGAGAAAAACAgZAKAAAAAME BkAoAAAAAwQGQGgAAAADAwEGQCgAAAADBAgAaAAAAAMBAQZAaAAAAAMDAQZA aAAAAAMDAQsAAQABAgACAwADBAAEBQAFBgAGBwAHCAAICQAICgAKCwALDAAM DWgMDQ5oDA4PaAwPECAPEWgMERJoDAUAAA0FAAoAABIMaAxCBAAAAAYBAgME BQAGBgcICgAFBgsMDQUACgYODxESDA0XBAAAAAAAAAAW 2026-09-19T04:00:39Z